Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Cipla plans to file...

    Cipla plans to file over dozen new drug applications for FY20

    GarimaWritten by Garima Published On 2019-05-27T09:30:38+05:30  |  Updated On 16 Aug 2021 10:37 AM IST

    In another key market of South Africa, during the current fiscal year, Cipla is looking to strengthen its OTC (over-the-counter) business.


    New Delhi: Drug firm Cipla said it is looking at continued growth across all its key markets in the current fiscal year and plans to file over 12 abbreviated new drug applications during the period. Highlighting the priorities for FY20, the company said for the Indian market, it is looking at strong growth in existing franchises including respiratory and ramp-up of chronic therapies such as diabetes, cardio and women health, according to Cipla's latest investor presentation.


    For the US market, where the company has seen significant growth driven by ramp-up across key differentiated products in FY19, it is looking to scale-up last fiscal's launches and also introduce more products in FY20 while continuing the speciality investments.


    Read Also: Cipla to acquire 26 percent stake in AMP Solar Power Systems


    In another key market of South Africa, during the current fiscal year, Cipla is looking to strengthen its OTC (over-the-counter) business.


    In the rest of the world (RoW) market, the company will be focussing on continuing market leadership in key regions, it added.


    For the current fiscal year, the company will focus on complex and differentiated assets and plans to file over 12 abbreviated new drug applications (ANDAs), while also ensuring compliance at all its facilities globally.


    Cipla posted a net profit of Rs 1,492.44 crore for the 2018-19 fiscal as against Rs 1,416.57 crore in 2017-18.


    Read Also: Cipla Q4 net profit jumps 133 pc at Rs 357.68 crore; plans fundraising of Rs 6000 crore


    Total revenue from operations for the last fiscal stood at Rs 16,362.41 crore. It was Rs 15,219.25 crore in the preceding financial year.

    abbreviated new drug applicationsANDAsblood sugarcardiochronic therapiesCiplaCipla financial resultscipla FY20cipla otc businessdiabetesDrug firm CipladrugsFinancial resultsNew DelhiOTCover-the-counterwomen health
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok